Review




Structured Review

Corning Life Sciences pooled human liver s9 hls9
Compound depletion of a starting concentration of 1 µM of (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) p-octopamine, (J) p-synephrine, (K) phenethylamine and (L) tyramine in incubations with human liver <t>S9</t> (HSL9) and co-factor mix (= full reaction mix; dots ), in incubations with co-factor mix and without <t>HLS9</t> (= w/o human liver S9; squares ) and in incubations with HLS9 and without co-factor mix (= w/o co-factor mix; triangles ); data points (± SD) are shown as the natural logarithm (Ln) of the percentage of the parent compound at time point zero; K represents the elimination rate constant (/min) derived from the slope of compound depletion in full reaction mix incubations
Pooled Human Liver S9 Hls9, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pooled human liver s9 hls9/product/Corning Life Sciences
Average 90 stars, based on 1 article reviews
pooled human liver s9 hls9 - by Bioz Stars, 2026-03
90/100 stars

Images

1) Product Images from "Quantitative in vitro-to-in vivo extrapolation of human adrenergic and trace amine-associated receptor 1 potencies of pre-workout supplement ingredients using physiologically based kinetic modelling-based reverse dosimetry"

Article Title: Quantitative in vitro-to-in vivo extrapolation of human adrenergic and trace amine-associated receptor 1 potencies of pre-workout supplement ingredients using physiologically based kinetic modelling-based reverse dosimetry

Journal: Archives of Toxicology

doi: 10.1007/s00204-025-03992-7

Compound depletion of a starting concentration of 1 µM of (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) p-octopamine, (J) p-synephrine, (K) phenethylamine and (L) tyramine in incubations with human liver S9 (HSL9) and co-factor mix (= full reaction mix; dots ), in incubations with co-factor mix and without HLS9 (= w/o human liver S9; squares ) and in incubations with HLS9 and without co-factor mix (= w/o co-factor mix; triangles ); data points (± SD) are shown as the natural logarithm (Ln) of the percentage of the parent compound at time point zero; K represents the elimination rate constant (/min) derived from the slope of compound depletion in full reaction mix incubations
Figure Legend Snippet: Compound depletion of a starting concentration of 1 µM of (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) p-octopamine, (J) p-synephrine, (K) phenethylamine and (L) tyramine in incubations with human liver S9 (HSL9) and co-factor mix (= full reaction mix; dots ), in incubations with co-factor mix and without HLS9 (= w/o human liver S9; squares ) and in incubations with HLS9 and without co-factor mix (= w/o co-factor mix; triangles ); data points (± SD) are shown as the natural logarithm (Ln) of the percentage of the parent compound at time point zero; K represents the elimination rate constant (/min) derived from the slope of compound depletion in full reaction mix incubations

Techniques Used: Concentration Assay, Derivative Assay

Normalised sensitivity coefficients (NSCs) of the C max plasma venous simulations to the critical input parameters for all studied phenethylamine (PEA) analogues at an oral dose of 1 mg/kg bw; (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) phenethylamine, (J) p-octopamine, (K) p-synephrine and (L) tyramine. FQre = fractional tissue blood flow rest of body, FQte = fractional testes blood, FQsp = fractional spleen blood flow, FQmu = fractional muscle blood flow, FQh = fractional hepatic blood flow, FQki = fractional kidney blood flow, FQhe = fractional heart blood flow, FQgu = fractional gut blood flow, FQbr = fractional brain blood flow, FQbo = fractional bone blood flow, FQad = fractional adipose tissue blood flow, CO = cardiac output, FVre = fractional volume rest of body, FVpl = fractional volume plasma, FVar = fractional volume arterial blood, FVve = fractional volume venous blood, FVte = fractional volume testes, FVsp = fractional volume spleen, FVsk = fractional volume skin, FVmu = fractional volume muscle, FVlu = fractional volume lung, FVli = fractional volume liver, FVki = fractional volume kidney, FVhe = fractional volume heart, FVgu = fractional volume gut, FVbr = fractional volume brain, FVbo = fractional volume bone, FVad = fractional volume adipose tissue, BW = body weight, BP = blood/plasma ratio, fuliver = fraction unbound liver, fup = fraction unbound in plasma, CLint = intrinsic clearance, fuinc = fraction unbound in human liver S9 incubation, SF = scaling factor of human liver S9 to a whole human liver, Kpre = rest of body:plasma partition coefficient, Kpte = testes:plasma partition coefficient, Kpsp = spleen:plasma partition coefficient, Kpsk = skin:plasma partition coefficient, Kpmu = muscle:plasma partition coefficient, Kplu = lung:plasma partition coefficient, Kpli = liver:plasma partition coefficient, Kpki = kidney:plasma partition coefficient, Kphe = heart:plasma partition coefficient, Kpgu = gut:plasma partition coefficient, Kpbr = brain:plasma partition coefficient, Kpbo = bone:plasma partition coefficient, Kpad = adipose:plasma partition coefficient, fa = fraction absorbed, ka = absorption rate constant
Figure Legend Snippet: Normalised sensitivity coefficients (NSCs) of the C max plasma venous simulations to the critical input parameters for all studied phenethylamine (PEA) analogues at an oral dose of 1 mg/kg bw; (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) phenethylamine, (J) p-octopamine, (K) p-synephrine and (L) tyramine. FQre = fractional tissue blood flow rest of body, FQte = fractional testes blood, FQsp = fractional spleen blood flow, FQmu = fractional muscle blood flow, FQh = fractional hepatic blood flow, FQki = fractional kidney blood flow, FQhe = fractional heart blood flow, FQgu = fractional gut blood flow, FQbr = fractional brain blood flow, FQbo = fractional bone blood flow, FQad = fractional adipose tissue blood flow, CO = cardiac output, FVre = fractional volume rest of body, FVpl = fractional volume plasma, FVar = fractional volume arterial blood, FVve = fractional volume venous blood, FVte = fractional volume testes, FVsp = fractional volume spleen, FVsk = fractional volume skin, FVmu = fractional volume muscle, FVlu = fractional volume lung, FVli = fractional volume liver, FVki = fractional volume kidney, FVhe = fractional volume heart, FVgu = fractional volume gut, FVbr = fractional volume brain, FVbo = fractional volume bone, FVad = fractional volume adipose tissue, BW = body weight, BP = blood/plasma ratio, fuliver = fraction unbound liver, fup = fraction unbound in plasma, CLint = intrinsic clearance, fuinc = fraction unbound in human liver S9 incubation, SF = scaling factor of human liver S9 to a whole human liver, Kpre = rest of body:plasma partition coefficient, Kpte = testes:plasma partition coefficient, Kpsp = spleen:plasma partition coefficient, Kpsk = skin:plasma partition coefficient, Kpmu = muscle:plasma partition coefficient, Kplu = lung:plasma partition coefficient, Kpli = liver:plasma partition coefficient, Kpki = kidney:plasma partition coefficient, Kphe = heart:plasma partition coefficient, Kpgu = gut:plasma partition coefficient, Kpbr = brain:plasma partition coefficient, Kpbo = bone:plasma partition coefficient, Kpad = adipose:plasma partition coefficient, fa = fraction absorbed, ka = absorption rate constant

Techniques Used: Clinical Proteomics, Analogues, Incubation

Normalised sensitivity coefficients (NSCs) of the C max plasma venous simulations to the most critical input parameters for all studied phenethylamine (PEA) analogues at an oral dose of 1 mg/kg bw; for each parameter, data points of the 12 different PEA analogues are shown; FQmu, fractional muscle blood flow; FQh, fractional hepatic blood flow (venous side); FQki, fractional kidney blood flow; FQbr, fractional brain blood flow; FQre, fractional tissue blood flow rest of body; FVli, fractional liver volume; fuliver, fraction unbound in liver; Clint, in vitro intrinsic hepatic metabolic clearance; fuinc, fraction unbound in the in vitro liver S9 incubation; SF, scaling factor for mg liver S9 per gram liver; fa, fraction absorbed; ka, absorption rate constant
Figure Legend Snippet: Normalised sensitivity coefficients (NSCs) of the C max plasma venous simulations to the most critical input parameters for all studied phenethylamine (PEA) analogues at an oral dose of 1 mg/kg bw; for each parameter, data points of the 12 different PEA analogues are shown; FQmu, fractional muscle blood flow; FQh, fractional hepatic blood flow (venous side); FQki, fractional kidney blood flow; FQbr, fractional brain blood flow; FQre, fractional tissue blood flow rest of body; FVli, fractional liver volume; fuliver, fraction unbound in liver; Clint, in vitro intrinsic hepatic metabolic clearance; fuinc, fraction unbound in the in vitro liver S9 incubation; SF, scaling factor for mg liver S9 per gram liver; fa, fraction absorbed; ka, absorption rate constant

Techniques Used: Clinical Proteomics, Analogues, In Vitro, Incubation

Correlations of Normalized Sensitivity Coefficients (NSCs) and the modelled intrinsic hepatic metabolic intrinsic clearance (CL met ) for the NSCs of (A) CLint (= in vitro intrinsic hepatic metabolic clearance), (B) FQh (= fractional hepatic blood flow, venous side), (C) FVli (= fractional liver volume), (D) fuliver (= fraction unbound in liver), (E) fuinc (= fraction unbound in the in vitro liver S9 incubation) and (F) SF (= scaling factor for mg liver S9 per gram liver)
Figure Legend Snippet: Correlations of Normalized Sensitivity Coefficients (NSCs) and the modelled intrinsic hepatic metabolic intrinsic clearance (CL met ) for the NSCs of (A) CLint (= in vitro intrinsic hepatic metabolic clearance), (B) FQh (= fractional hepatic blood flow, venous side), (C) FVli (= fractional liver volume), (D) fuliver (= fraction unbound in liver), (E) fuinc (= fraction unbound in the in vitro liver S9 incubation) and (F) SF (= scaling factor for mg liver S9 per gram liver)

Techniques Used: In Vitro, Incubation



Similar Products

90
Corning Life Sciences pooled human liver s9 hls9
Compound depletion of a starting concentration of 1 µM of (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) p-octopamine, (J) p-synephrine, (K) phenethylamine and (L) tyramine in incubations with human liver <t>S9</t> (HSL9) and co-factor mix (= full reaction mix; dots ), in incubations with co-factor mix and without <t>HLS9</t> (= w/o human liver S9; squares ) and in incubations with HLS9 and without co-factor mix (= w/o co-factor mix; triangles ); data points (± SD) are shown as the natural logarithm (Ln) of the percentage of the parent compound at time point zero; K represents the elimination rate constant (/min) derived from the slope of compound depletion in full reaction mix incubations
Pooled Human Liver S9 Hls9, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pooled human liver s9 hls9/product/Corning Life Sciences
Average 90 stars, based on 1 article reviews
pooled human liver s9 hls9 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Corning Life Sciences pooled human liver s9 (hls9)
Compound depletion of a starting concentration of 1 µM of (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) p-octopamine, (J) p-synephrine, (K) phenethylamine and (L) tyramine in incubations with human liver <t>S9</t> (HSL9) and co-factor mix (= full reaction mix; dots ), in incubations with co-factor mix and without <t>HLS9</t> (= w/o human liver S9; squares ) and in incubations with HLS9 and without co-factor mix (= w/o co-factor mix; triangles ); data points (± SD) are shown as the natural logarithm (Ln) of the percentage of the parent compound at time point zero; K represents the elimination rate constant (/min) derived from the slope of compound depletion in full reaction mix incubations
Pooled Human Liver S9 (Hls9), supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pooled human liver s9 (hls9)/product/Corning Life Sciences
Average 90 stars, based on 1 article reviews
pooled human liver s9 (hls9) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Gentest Corp pooled human liver s9 fractions (hls9)
Compound depletion of a starting concentration of 1 µM of (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) p-octopamine, (J) p-synephrine, (K) phenethylamine and (L) tyramine in incubations with human liver <t>S9</t> (HSL9) and co-factor mix (= full reaction mix; dots ), in incubations with co-factor mix and without <t>HLS9</t> (= w/o human liver S9; squares ) and in incubations with HLS9 and without co-factor mix (= w/o co-factor mix; triangles ); data points (± SD) are shown as the natural logarithm (Ln) of the percentage of the parent compound at time point zero; K represents the elimination rate constant (/min) derived from the slope of compound depletion in full reaction mix incubations
Pooled Human Liver S9 Fractions (Hls9), supplied by Gentest Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pooled human liver s9 fractions (hls9)/product/Gentest Corp
Average 90 stars, based on 1 article reviews
pooled human liver s9 fractions (hls9) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Sekisui XenoTech human (pooled male and female) liver s9 fraction (hls9) for phase ii metabolism
Compound depletion of a starting concentration of 1 µM of (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) p-octopamine, (J) p-synephrine, (K) phenethylamine and (L) tyramine in incubations with human liver <t>S9</t> (HSL9) and co-factor mix (= full reaction mix; dots ), in incubations with co-factor mix and without <t>HLS9</t> (= w/o human liver S9; squares ) and in incubations with HLS9 and without co-factor mix (= w/o co-factor mix; triangles ); data points (± SD) are shown as the natural logarithm (Ln) of the percentage of the parent compound at time point zero; K represents the elimination rate constant (/min) derived from the slope of compound depletion in full reaction mix incubations
Human (Pooled Male And Female) Liver S9 Fraction (Hls9) For Phase Ii Metabolism, supplied by Sekisui XenoTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human (pooled male and female) liver s9 fraction (hls9) for phase ii metabolism/product/Sekisui XenoTech
Average 90 stars, based on 1 article reviews
human (pooled male and female) liver s9 fraction (hls9) for phase ii metabolism - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Sekisui XenoTech pooled human liver s9 fraction hls9
Compound depletion of a starting concentration of 1 µM of (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) p-octopamine, (J) p-synephrine, (K) phenethylamine and (L) tyramine in incubations with human liver <t>S9</t> (HSL9) and co-factor mix (= full reaction mix; dots ), in incubations with co-factor mix and without <t>HLS9</t> (= w/o human liver S9; squares ) and in incubations with HLS9 and without co-factor mix (= w/o co-factor mix; triangles ); data points (± SD) are shown as the natural logarithm (Ln) of the percentage of the parent compound at time point zero; K represents the elimination rate constant (/min) derived from the slope of compound depletion in full reaction mix incubations
Pooled Human Liver S9 Fraction Hls9, supplied by Sekisui XenoTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pooled human liver s9 fraction hls9/product/Sekisui XenoTech
Average 90 stars, based on 1 article reviews
pooled human liver s9 fraction hls9 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Sekisui XenoTech human liver s9 (pool size, 50; hls9)
Compound depletion of a starting concentration of 1 µM of (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) p-octopamine, (J) p-synephrine, (K) phenethylamine and (L) tyramine in incubations with human liver <t>S9</t> (HSL9) and co-factor mix (= full reaction mix; dots ), in incubations with co-factor mix and without <t>HLS9</t> (= w/o human liver S9; squares ) and in incubations with HLS9 and without co-factor mix (= w/o co-factor mix; triangles ); data points (± SD) are shown as the natural logarithm (Ln) of the percentage of the parent compound at time point zero; K represents the elimination rate constant (/min) derived from the slope of compound depletion in full reaction mix incubations
Human Liver S9 (Pool Size, 50; Hls9), supplied by Sekisui XenoTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human liver s9 (pool size, 50; hls9)/product/Sekisui XenoTech
Average 90 stars, based on 1 article reviews
human liver s9 (pool size, 50; hls9) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Compound depletion of a starting concentration of 1 µM of (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) p-octopamine, (J) p-synephrine, (K) phenethylamine and (L) tyramine in incubations with human liver S9 (HSL9) and co-factor mix (= full reaction mix; dots ), in incubations with co-factor mix and without HLS9 (= w/o human liver S9; squares ) and in incubations with HLS9 and without co-factor mix (= w/o co-factor mix; triangles ); data points (± SD) are shown as the natural logarithm (Ln) of the percentage of the parent compound at time point zero; K represents the elimination rate constant (/min) derived from the slope of compound depletion in full reaction mix incubations

Journal: Archives of Toxicology

Article Title: Quantitative in vitro-to-in vivo extrapolation of human adrenergic and trace amine-associated receptor 1 potencies of pre-workout supplement ingredients using physiologically based kinetic modelling-based reverse dosimetry

doi: 10.1007/s00204-025-03992-7

Figure Lengend Snippet: Compound depletion of a starting concentration of 1 µM of (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) p-octopamine, (J) p-synephrine, (K) phenethylamine and (L) tyramine in incubations with human liver S9 (HSL9) and co-factor mix (= full reaction mix; dots ), in incubations with co-factor mix and without HLS9 (= w/o human liver S9; squares ) and in incubations with HLS9 and without co-factor mix (= w/o co-factor mix; triangles ); data points (± SD) are shown as the natural logarithm (Ln) of the percentage of the parent compound at time point zero; K represents the elimination rate constant (/min) derived from the slope of compound depletion in full reaction mix incubations

Article Snippet: In vitro intrinsic hepatic clearance (CL int ) values of the phenethylamine analogues were determined in experiments with pooled human liver S9 (HLS9; Corning, Woburn, MA, USA and Gibco, USA), by measuring the rate of compound depletion.

Techniques: Concentration Assay, Derivative Assay

Normalised sensitivity coefficients (NSCs) of the C max plasma venous simulations to the critical input parameters for all studied phenethylamine (PEA) analogues at an oral dose of 1 mg/kg bw; (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) phenethylamine, (J) p-octopamine, (K) p-synephrine and (L) tyramine. FQre = fractional tissue blood flow rest of body, FQte = fractional testes blood, FQsp = fractional spleen blood flow, FQmu = fractional muscle blood flow, FQh = fractional hepatic blood flow, FQki = fractional kidney blood flow, FQhe = fractional heart blood flow, FQgu = fractional gut blood flow, FQbr = fractional brain blood flow, FQbo = fractional bone blood flow, FQad = fractional adipose tissue blood flow, CO = cardiac output, FVre = fractional volume rest of body, FVpl = fractional volume plasma, FVar = fractional volume arterial blood, FVve = fractional volume venous blood, FVte = fractional volume testes, FVsp = fractional volume spleen, FVsk = fractional volume skin, FVmu = fractional volume muscle, FVlu = fractional volume lung, FVli = fractional volume liver, FVki = fractional volume kidney, FVhe = fractional volume heart, FVgu = fractional volume gut, FVbr = fractional volume brain, FVbo = fractional volume bone, FVad = fractional volume adipose tissue, BW = body weight, BP = blood/plasma ratio, fuliver = fraction unbound liver, fup = fraction unbound in plasma, CLint = intrinsic clearance, fuinc = fraction unbound in human liver S9 incubation, SF = scaling factor of human liver S9 to a whole human liver, Kpre = rest of body:plasma partition coefficient, Kpte = testes:plasma partition coefficient, Kpsp = spleen:plasma partition coefficient, Kpsk = skin:plasma partition coefficient, Kpmu = muscle:plasma partition coefficient, Kplu = lung:plasma partition coefficient, Kpli = liver:plasma partition coefficient, Kpki = kidney:plasma partition coefficient, Kphe = heart:plasma partition coefficient, Kpgu = gut:plasma partition coefficient, Kpbr = brain:plasma partition coefficient, Kpbo = bone:plasma partition coefficient, Kpad = adipose:plasma partition coefficient, fa = fraction absorbed, ka = absorption rate constant

Journal: Archives of Toxicology

Article Title: Quantitative in vitro-to-in vivo extrapolation of human adrenergic and trace amine-associated receptor 1 potencies of pre-workout supplement ingredients using physiologically based kinetic modelling-based reverse dosimetry

doi: 10.1007/s00204-025-03992-7

Figure Lengend Snippet: Normalised sensitivity coefficients (NSCs) of the C max plasma venous simulations to the critical input parameters for all studied phenethylamine (PEA) analogues at an oral dose of 1 mg/kg bw; (A) β-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) phenethylamine, (J) p-octopamine, (K) p-synephrine and (L) tyramine. FQre = fractional tissue blood flow rest of body, FQte = fractional testes blood, FQsp = fractional spleen blood flow, FQmu = fractional muscle blood flow, FQh = fractional hepatic blood flow, FQki = fractional kidney blood flow, FQhe = fractional heart blood flow, FQgu = fractional gut blood flow, FQbr = fractional brain blood flow, FQbo = fractional bone blood flow, FQad = fractional adipose tissue blood flow, CO = cardiac output, FVre = fractional volume rest of body, FVpl = fractional volume plasma, FVar = fractional volume arterial blood, FVve = fractional volume venous blood, FVte = fractional volume testes, FVsp = fractional volume spleen, FVsk = fractional volume skin, FVmu = fractional volume muscle, FVlu = fractional volume lung, FVli = fractional volume liver, FVki = fractional volume kidney, FVhe = fractional volume heart, FVgu = fractional volume gut, FVbr = fractional volume brain, FVbo = fractional volume bone, FVad = fractional volume adipose tissue, BW = body weight, BP = blood/plasma ratio, fuliver = fraction unbound liver, fup = fraction unbound in plasma, CLint = intrinsic clearance, fuinc = fraction unbound in human liver S9 incubation, SF = scaling factor of human liver S9 to a whole human liver, Kpre = rest of body:plasma partition coefficient, Kpte = testes:plasma partition coefficient, Kpsp = spleen:plasma partition coefficient, Kpsk = skin:plasma partition coefficient, Kpmu = muscle:plasma partition coefficient, Kplu = lung:plasma partition coefficient, Kpli = liver:plasma partition coefficient, Kpki = kidney:plasma partition coefficient, Kphe = heart:plasma partition coefficient, Kpgu = gut:plasma partition coefficient, Kpbr = brain:plasma partition coefficient, Kpbo = bone:plasma partition coefficient, Kpad = adipose:plasma partition coefficient, fa = fraction absorbed, ka = absorption rate constant

Article Snippet: In vitro intrinsic hepatic clearance (CL int ) values of the phenethylamine analogues were determined in experiments with pooled human liver S9 (HLS9; Corning, Woburn, MA, USA and Gibco, USA), by measuring the rate of compound depletion.

Techniques: Clinical Proteomics, Analogues, Incubation

Normalised sensitivity coefficients (NSCs) of the C max plasma venous simulations to the most critical input parameters for all studied phenethylamine (PEA) analogues at an oral dose of 1 mg/kg bw; for each parameter, data points of the 12 different PEA analogues are shown; FQmu, fractional muscle blood flow; FQh, fractional hepatic blood flow (venous side); FQki, fractional kidney blood flow; FQbr, fractional brain blood flow; FQre, fractional tissue blood flow rest of body; FVli, fractional liver volume; fuliver, fraction unbound in liver; Clint, in vitro intrinsic hepatic metabolic clearance; fuinc, fraction unbound in the in vitro liver S9 incubation; SF, scaling factor for mg liver S9 per gram liver; fa, fraction absorbed; ka, absorption rate constant

Journal: Archives of Toxicology

Article Title: Quantitative in vitro-to-in vivo extrapolation of human adrenergic and trace amine-associated receptor 1 potencies of pre-workout supplement ingredients using physiologically based kinetic modelling-based reverse dosimetry

doi: 10.1007/s00204-025-03992-7

Figure Lengend Snippet: Normalised sensitivity coefficients (NSCs) of the C max plasma venous simulations to the most critical input parameters for all studied phenethylamine (PEA) analogues at an oral dose of 1 mg/kg bw; for each parameter, data points of the 12 different PEA analogues are shown; FQmu, fractional muscle blood flow; FQh, fractional hepatic blood flow (venous side); FQki, fractional kidney blood flow; FQbr, fractional brain blood flow; FQre, fractional tissue blood flow rest of body; FVli, fractional liver volume; fuliver, fraction unbound in liver; Clint, in vitro intrinsic hepatic metabolic clearance; fuinc, fraction unbound in the in vitro liver S9 incubation; SF, scaling factor for mg liver S9 per gram liver; fa, fraction absorbed; ka, absorption rate constant

Article Snippet: In vitro intrinsic hepatic clearance (CL int ) values of the phenethylamine analogues were determined in experiments with pooled human liver S9 (HLS9; Corning, Woburn, MA, USA and Gibco, USA), by measuring the rate of compound depletion.

Techniques: Clinical Proteomics, Analogues, In Vitro, Incubation

Correlations of Normalized Sensitivity Coefficients (NSCs) and the modelled intrinsic hepatic metabolic intrinsic clearance (CL met ) for the NSCs of (A) CLint (= in vitro intrinsic hepatic metabolic clearance), (B) FQh (= fractional hepatic blood flow, venous side), (C) FVli (= fractional liver volume), (D) fuliver (= fraction unbound in liver), (E) fuinc (= fraction unbound in the in vitro liver S9 incubation) and (F) SF (= scaling factor for mg liver S9 per gram liver)

Journal: Archives of Toxicology

Article Title: Quantitative in vitro-to-in vivo extrapolation of human adrenergic and trace amine-associated receptor 1 potencies of pre-workout supplement ingredients using physiologically based kinetic modelling-based reverse dosimetry

doi: 10.1007/s00204-025-03992-7

Figure Lengend Snippet: Correlations of Normalized Sensitivity Coefficients (NSCs) and the modelled intrinsic hepatic metabolic intrinsic clearance (CL met ) for the NSCs of (A) CLint (= in vitro intrinsic hepatic metabolic clearance), (B) FQh (= fractional hepatic blood flow, venous side), (C) FVli (= fractional liver volume), (D) fuliver (= fraction unbound in liver), (E) fuinc (= fraction unbound in the in vitro liver S9 incubation) and (F) SF (= scaling factor for mg liver S9 per gram liver)

Article Snippet: In vitro intrinsic hepatic clearance (CL int ) values of the phenethylamine analogues were determined in experiments with pooled human liver S9 (HLS9; Corning, Woburn, MA, USA and Gibco, USA), by measuring the rate of compound depletion.

Techniques: In Vitro, Incubation